Helixor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Helixor

What is Helixor? Overview

Property Description
Active Ingredient Viscum album L. (European Mistletoe) liquid extract
Form Sterile solution for injection (in ampoules)
Pharmacological Class Biological Response Modifier (BRM) / Immunomodulator
Common Use Complementary and supportive therapy
Origin Plant-based (Herbal extract)

What Type of Medicine is Helixor? (Identity & Classification)

Helixor is a specific brand of injectable, plant-based medicinal product derived from the fresh herb of the European mistletoe plant (Viscum album L.). Manufactured by Helixor Heilmittel GmbH in Germany, it is classified as an anthroposophic medicine and a highly standardized herbal medicinal product primarily used in integrative oncology. Helixor is scientifically categorized as a Biological Response Modifier (BRM), reflecting its intended role in modulating the patient's own biological systems, particularly the immune response. It is supplied as a sterile, liquid solution for injection, ensuring the complex components are delivered directly for systemic absorption via the subcutaneous route of administration.


What is Helixor Made Of? (Composition & Origin)

The active ingredients in Helixor are the complex compounds contained within its unique aqueous cold extract of Viscum album L., including the key therapeutic proteins known as mistletoe lectins (ML) and viscotoxins. Unlike some other mistletoe preparations, the Helixor brand uses a proprietary, gentle, cold extraction process designed for maximizing the preservation of temperature-sensitive components. The manufacturing process is designed to ensure a consistent quality regarding these key components, as the extract's use is based on its established composition and immunomodulating properties. The composition is further characterized by the host tree from which the mistletoe was harvested (e.g., fir, apple, or pine), leading to distinct product variants (Helixor A, M, or P).


What is the Overall Goal of Helixor Therapy? (General Purpose)

The overall goal of using Helixor is to provide complementary, supportive care aimed at strengthening the body's natural defenses and improving the patient’s general well-being and quality of life. As an immunomodulator, the therapy is primarily intended to help the body better cope with chronic health challenges and the demands of conventional treatments, serving as a pillar of supportive care. Patients using Helixor seek to benefit from an improved sense of vitality and greater support for their immune function as part of a comprehensive, integrated treatment plan.

Regulatory References

  1. National Cancer Institute (NCI)

What side effects are possible with Helixor?

Possible Side Effects and Safety Information

The documented safety profile for injectable Viscum album L. extracts, including Helixor, is primarily characterized by reactions related to the body's immune response, as classified in regulatory documents.

Adverse Reaction Categories and Frequency

Adverse reactions are formally classified into frequency categories, which correspond to specific System Organ Classes (SOCs) in regulatory safety summaries.

Classification System Organ Class (SOC) Documented Effects
Very Common / Common General disorders and administration site conditions Local injection site reactions (erythema, swelling, induration), mild, transient increases in body temperature (fever/pyrexia), headache, and malaise.
Uncommon / Rare Immune system disorders, Skin and subcutaneous tissue disorders Generalized allergic reactions, urticaria, chills, rash, and generalized pruritus (itching).
Rare / Very Rare Immune system disorders Serious hypersensitivity reactions, including anaphylaxis, which is the most significant potential safety concern.

Safety Patterns and Constraints

Systemic effects, such as mild fever or local inflammation, are more frequently observed at the start of treatment or following a dose escalation. These reactions are often cited as signs of the intended immunomodulatory action.

Official labeling specifies key constraints. The medicine is contraindicated in individuals with active inflammatory diseases or autoimmune conditions due to its immunomodulating properties. Additionally, use during pregnancy and lactation is generally contraindicated as safety in these populations has not been established in regulatory assessments.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of injectable Viscum album L. extract (Helixor) is associated with an acute systemic intoxication profile documented in regulatory and toxicology summaries.

Systemic Overdose Manifestations Severe Life-Threatening Outcomes
Gastrointestinal disturbances (vomiting, nausea, diarrhoea). Hepatotoxicity (reversible liver injury/damage).
Pronounced systemic reactions (severe flu-like symptoms). Cardiovascular collapse, severe hypotension, and bradycardia.
Central Nervous System effects, including seizures and coma.

Overdose Classifications

Classification Element Official Regulatory Description
Severity classification Classified as serious systemic intoxication due to the potential for major organ system involvement (cardiac, CNS, hepatic).
Overdose-context constraints No specific antidote is documented for the intoxication. Treatment focuses exclusively on symptomatic and supportive measures.

Official Overdose Statements

Acute high-dose exposure is classified as serious systemic intoxication due to the potential for major organ system involvement. In the event of suspected overdose, official regulatory information mandates that immediate medical attention is required. Urgent medical help must be sought for any manifestation of severe clinical signs, such as loss of consciousness, seizures, or significant cardiovascular changes.

Treatment is defined as symptomatic and supportive, addressing the specific clinical presentations, with a focus on monitoring vital signs and laboratory parameters. Hospital observation and intensive monitoring are required due to the potential for delayed or severe cardiac, neurological, or hepatic effects. The documented severity of these risks dictates the necessity of contacting emergency services without delay.

Therapeutic Uses of Helixor

What Helixor Treats: Main Uses and Benefits

The use of Helixor centers on providing complementary and supportive care within the domain of Integrative Oncology, is applied across domains where additional symptomatic support is needed, and supports general well-being during symptomatic phases. Mistletoe extracts are commonly used as a complementary therapy in people with cancer, often prescribed as supportive care.

The therapy is relevant for managing symptoms that interfere with daily comfort, particularly those constitutional and systemic symptoms that often cluster together. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, primarily for patients with malignant tumor diseases, specific benign tumor diseases, and precancerous lesions.


Supporting Tolerability and Quality of Life

This therapy is applied across domains where additional symptomatic support is needed to ease the overall symptom burden, which contributes to improved comfort during periods of heightened symptoms. It supports patients during episodes of heightened discomfort and may assist with maintaining functional stability during demanding periods like chemotherapy or radiation.


Quick Fact: Symptomatic Support During Treatment This therapy assists with maintaining functional stability and may be part of symptomatic management for issues such as persistent fatigue, poor appetite, and nausea that can be disruptive during conventional treatment phases.

Regulatory References

  1. National Cancer Institute (NCI) PDQ Summary

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Helixor — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for Helixor, as stated in governmental regulatory documents, such as the Summary of Product Characteristics (SmPC) in authorizing European nations.


Eligibility Scope

Classification Population/Condition Regulatory Status
Allowed Use Adults with malignant tumor diseases (supportive care) Established
Contraindicated Hypersensitivity to mistletoe preparations Absolute exclusion
Contraindicated Acute inflammatory diseases or high fever (gt 38 C) Absolute exclusion
Contraindicated Progressive autoimmune diseases, chronic granulomatous diseases, uncontrolled hyperthyroidism Absolute exclusion
Not Recommended Children and adolescents Insufficient data
Not Recommended Pregnancy and breastfeeding Insufficient safety data

Eligibility-Related Restrictions

Restriction Type Specific Rule
Concomitant Therapy Use is generally restricted or contradicted with other immune-stimulating/modulating therapies, except for conventional cytotoxic drugs.
Organ Dysfunction Specific usage restrictions for moderate renal or hepatic impairment are typically not documented in the official labeling.

Connection to the overall eligibility profile: Regulatory documents define that use is established only in adults seeking supportive care for tumor diseases, while strictly contraindicating use in patients with active immune system conditions, such as high fever or progressive autoimmune diseases. The status for children, adolescents, and pregnant/breastfeeding women is classified as not recommended due to a lack of sufficient established safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Helixor, based strictly on government regulatory information, such as the Summary of Product Characteristics (SmPC) and equivalent national authority documents.


Pharmacodynamic Interaction Profile

Regulatory documentation defines the primary interaction focus around the product's classification as a Biological Response Modifier (BRM), a plant-based medicinal product derived from Viscum album L..

  • Immunomodulators and Immunosuppressants: Co-administration with other medicinal products that significantly influence the immune system is noted as a potential pharmacodynamic interaction. This requires consideration due to the possibility of additive or counteracting effects on the patient's immune status.

Absence of Documented Pharmacokinetic Interactions

Regulatory documents generally do not specify complex pharmacokinetic (PK) interactions. This means there are no officially documented interaction patterns involving specific:

  • Metabolic Enzymes: No documented inhibition or induction of CYP enzymes.
  • Drug Transporters: No documented interactions involving P-gp, OATP, or other drug transporters.
  • Exposure Modification: No official statements document substances that increase or decrease the plasma concentration ( AUC or Cmax) of Helixor, or vice versa.

Administration Restrictions

Regulatory labeling does not document mandatory timing requirements. Furthermore, official prescribing information does not list specific interactions with food, alcohol, or other herbal products.

Mechanism of Action

Modulation of Immune Cell Activity

Helixor engages mechanisms that stimulate immune cells such as natural killer (NK) cells and macrophages, thereby affecting their functional profile. This leads to the enhanced release of specific cytokines and an increase in the number and activity of these key immune components, influencing systemic homeostasis.


Targeting Cell Cycle and Survival Pathways

The drug's components, including mistletoe lectins and viscotoxins, act on pathways that regulate cellular proliferation and programmed cell death (apoptosis). By interfering with ribosomal protein synthesis and inhibiting the cell cycle, Helixor initiates or suppresses signaling sequences that modulate the consequences of cellular proliferation and survival pathway activation in targeted systems.


Regulating Inflammatory Signaling Cascades

Helixor modifies early molecular steps in inflammatory pathways, notably through interaction with the Toll-like receptor 4 (TLR4) and downstream NF-kappaB and MAPK pathways. This engagement influences the downstream effects of inflammatory signaling by reducing the production of pro-inflammatory mediators, leading to an alteration in local mediator concentration within affected tissues.

Dosage and Administration Information

Administration Methods

Helixor is typically administered through subcutaneous injection, which involves delivering the solution into the fatty tissue layer just beneath the skin. Common injection sites include the abdomen, the upper arms, or the thighs. It is generally recommended to rotate the injection sites to maintain skin health and ensure consistent absorption.

In certain clinical settings, the substance may be administered through other methods, such as intravenous infusions or local injections near a specific site of interest. These alternative methods are determined based on the individual's overall health status and the specific goals of the supportive care plan.

Preparation and Handling

The solution is provided in glass ampoules. Proper handling involves ensuring the liquid is at room temperature before use. If the solution appears cloudy or contains visible particles, it should not be used.

Rhythm and Timing

The application of Helixor often follows a specific rhythmic schedule. This may involve injections administered several times per week, sometimes alternating with break periods where no injections are given. This rhythmic approach is intended to align with the body’s natural physiological cycles.

Integration into Care

The use of Helixor is often part of a broader integrative approach to health. It is frequently used alongside conventional medical treatments to support the patient's general well-being. Monitoring the physical response at the injection site is a standard part of the process, as localized reactions are a common and expected occurrence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Helixor

The research evidence for Helixor, like other mistletoe extracts, is drawn from various types of studies, including controlled clinical trials, systematic reviews that combine data from multiple studies, and observational studies that track patient experiences over time. The focus of this research is primarily on evaluating patterns related to patient well-being and whether it influences long-term clinical patterns when used alongside conventional treatment.


Evidence for Supportive Care and Quality of Life

This body of research has been applied in studies examining patient-reported experiences and how they change during periods of standard cancer care. Researchers have commonly used randomized controlled trials (RCTs) and meta-analyses. Outcomes related to systemic or functional imbalance were studied for, with the primary focus being Health-Related Quality of Life (HRQL) using standardized patient-reported scales.

  • Findings describe patterns observed in the studies where patients receiving the extract may have reported changes measured during the study period related to their quality of life. Meta-analyses and systematic reviews have aggregated data from various mistletoe extract trials describing patterns related to global quality of life scores.
  • Evidence quality varies across studies, with regulators noting concerns about older RCTs, often due to the inherent difficulty of effectively blinding. Findings were mixed regarding general well-being and functional capacity. Therefore, certainty remains low for some of these quality-of-life findings.

Studies on Long-Term Outcomes and Disease Progression

Research has also explored long-term disease outcomes such as Overall Survival (OS) and Disease-Free Survival (DFS). This evidence is generally considered to be of a Low to Moderate level, often relying on retrospective analyses.

  • When data from similar extracts in RCTs were pooled, they data show patterns related to overall survival; however, this pooled effect became non-significant when active comparators were added. This indicates that the findings were mixed, and results apply only to the populations studied.
  • Data for certain groups remain insufficient, as the majority of trials results apply only to the populations studied (adults with solid tumors). Long-term observational studies contribute to the broader evidence landscape by showing real-world practice patterns, though these long-term effects are not fully established by prospective, gold-standard RCTs.

Key Studies & References

  1. Mistletoe in cancer: a systematic review on controlled clinical trials
  2. Mistletoe Extracts (PDQ®): Integrative, alternative, and complementary therapies - Patient Information [NCI]

Frequently Asked Questions (FAQ)

Common questions about Helixor (FAQ)


Q: How is Helixor different from other mistletoe extracts available?

Helixor is distinguished by its proprietary, gentle cold extraction process, which aims to preserve the integrity of its components, such as mistletoe lectins and viscotoxins. Official documents note that the preparation is an aqueous fresh plant extract. Furthermore, the final product is defined by the specific host tree—such as fir (A), apple (M), or pine (P)—from which the mistletoe was harvested.


Q: Does Helixor interact with common vitamins or supplements?

Official regulatory summaries for Helixor do not specify documented interactions with common vitamins or nutritional supplements. The drug's interaction profile primarily focuses on other medicinal products, such as immunomodulators. It is also noted that the official labeling does not list specific interactions with food, alcohol, or other herbal products.


Q: Can Helixor be used at the same time as chemotherapy or radiation?

Regulatory documents state that use of Helixor is generally allowed alongside conventional cytotoxic drugs as part of a supportive treatment plan. The main constraint focuses on simultaneous use with other medicines that significantly influence the immune system, which is a potential pharmacological interaction. Official labeling details constraints regarding cytotoxic drugs but does not explicitly provide details for concurrent radiation therapy.


Q: Why is Helixor used in European countries more commonly than in the US?

Helixor is widely used and approved for therapeutic use in certain European countries, such as Germany and Austria. However, the regulatory status differs significantly in the United States. In the US, the extract is not approved by the FDA for treating cancer or other diseases, although it is listed in the Homeopathic Pharmacopoeia.


Q: Is there any difference in effect between the various Helixor preparations (A, P, M)?

The different Helixor preparations (A, M, P) are derived from mistletoe harvested from distinct host trees, such as fir, apple, or pine. Official product documents primarily note that the manufacturing process ensures consistent quality and standardization of key components like lectins across these variants. The summaries do not typically specify differences in therapeutic effects between these host tree types.


Q: How is the quality of the mistletoe extract standardized in Helixor?

Helixor is classified by regulatory authorities as a highly standardized herbal medicinal product. Official guidelines require the manufacturer's process to ensure a consistent quality with respect to the key therapeutic components, specifically mistletoe lectins and viscotoxins. This standardization aims to maintain a consistent composition.


Q: Can I travel with Helixor and do temperature changes affect it?

Official storage instructions state that the ampoules must be kept in a refrigerator (between +2 C and +8 C) and protected from light. It is essential that the product is not frozen and that exposure to temperatures above 25 C is avoided, even during travel. Consultation with a healthcare professional or pharmacist is recommended regarding specific travel logistics for refrigerated medication.


Q: Does Helixor have different uses or approvals in different countries?

Yes, the regulatory status and official use of Helixor vary significantly by country. Official administration guidelines are based on regulatory documentation in countries where it is approved, such as Germany and Austria. In other regions, the product may have a different regulatory status, for example, being unapproved for specific conditions or classified under alternative medicine systems.


Q: Do I need a prescription from a doctor to get Helixor?

In its country of origin, Germany, the product is often described as prescription-free and available from pharmacies. However, official guidelines emphasize that the patient's treatment protocol, dosing, and management must be established and monitored by a qualified physician. This is to ensure the medicine is managed and adjusted based on the patient's condition.


Q: When should I contact a healthcare professional about a side effect from Helixor?

General regulatory advice encourages individuals to immediately report any suspected adverse drug reaction concerning their therapies to a healthcare professional or pharmacist. Serious reactions, such as anaphylaxis (a severe allergic response), require immediate medical attention. A patient's physician is the appropriate source for specific guidance on which reactions require immediate reporting.


Q: Are there any specific concerns for older adults using Helixor?

While the product is officially approved for use in adults, regulatory guidance sometimes notes that older patients (aged 65 years and older) may be at an increased risk of adverse reactions due to potential changes in the immune system. The general constraint remains the same as for other adults: it is contraindicated in progressive autoimmune diseases.


Q: Is Helixor approved or recognized by the FDA in the United States?

Helixor is currently not approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer or other diseases in the United States. However, the mistletoe extract is listed in the Homeopathic Pharmacopoeia of the United States. This is a different regulatory classification than an approved prescription drug.


Q: Where is the research evidence for Helixor typically published?

Research evidence, including clinical trials and systematic reviews concerning Helixor, is published in peer-reviewed scientific and medical journals. Government-run bodies, such as the National Institutes of Health (NIH), also commonly summarize and review this evidence for public access.


Q: What should I do if the Helixor product looks cloudy or discolored?

Helixor is supplied as a sterile, clear liquid solution in ampoules, and regulatory requirements dictate it must be protected from light and temperature extremes. If the product appears cloudy, discolored, or shows visible changes, consultation with a pharmacist or prescribing healthcare professional is appropriate to ensure the sterility and quality of the solution before it is used.


Q: Does using Helixor mean I don't need my other prescribed medications?

Official documentation consistently describes Helixor as a complementary and supportive therapy, intended to be used alongside other standard care. Official safety information emphasizes that the product is not intended to replace standard medical treatments or other essential therapies prescribed by a healthcare team.


Q: Does using Helixor impact driving or operating machinery?

Regulatory guidance notes that common side effects, such as headache and malaise (a general feeling of discomfort or illness), may constitute a minor influence on the ability to drive or operate machinery. The presence of these effects suggests that caution should be considered.


Q: What type of healthcare professional usually prescribes or recommends Helixor?

The treatment protocol, including the individualized dose and frequency, is managed by a physician. The product is most often prescribed or recommended by clinicians who are experienced with its use, particularly those practicing integrative medicine or integrative oncology.


Q: Are there any mandatory monitoring tests required while using Helixor?

Official procedural guidance requires the physician to monitor the patient's reaction to the product, such as the response at the injection site or changes in body temperature. The core regulatory labeling summaries, however, do not typically document specific mandatory laboratory or clinical monitoring tests for all patients.


Q: Can Helixor be used by individuals who are vegan or vegetarian?

Official preparation descriptions state that Helixor is an aqueous fresh plant extract derived solely from the Viscum album L. plant. It is diluted with swirled water and filled sterile, and the official descriptions note that it is made without additives from animal products.


Q: What is the history behind the use of mistletoe in medicine?

The use of mistletoe extracts in medicine, which includes preparations like Helixor, has a long history. Its use was formally introduced in the early 20th century as part of the system known as anthroposophically-extended medicine.


Q: Is Helixor ever used outside of the conditions described in official documents?

Regulatory systems acknowledge that a licensed healthcare provider may choose to prescribe a drug for uses or in ways that are not specified in the official regulatory documentation. This practice is commonly referred to as off-label use.


Q: Does Helixor have any effect on mental clarity or mood?

The documented adverse drug reaction profile includes systemic effects like headache and malaise (a general feeling of discomfort or illness). While the product is used in supportive care, no specific effects on mental clarity or mood are listed as a direct adverse reaction in the official regulatory documents.


Q: Do official sources describe Helixor as a cure for any disease?

Official safety information explicitly states that Helixor is not a licensed cure for cancer or any other disease. Its official, documented purpose is strictly for complementary and supportive care aimed at improving the patient’s general well-being.

How should Helixor be stored and disposed of?

The official storage requirements for Helixor ampoules are designed to protect the stability of the liquid extract.

Storage Requirements

Condition Requirement
Temperature Store most preparations in a refrigerator (between +2 , C and +8 , C).
Protection Keep ampoules in the original outer box to protect the solution from light.
Avoidance Do not freeze the product; avoid temperatures above 25 , C.

Before administration, the ampoule should be warmed slightly in the hand. Used ampoules and sharps (needles/cannulae) must be placed in a sealable container for proper disposal, following local regulations for pharmaceutical and sharp waste. The accompanying syringe can typically be disposed of with household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Helixor found in:

A-Z Index: